Objectives: Despite decreasing mortality rates in acute lung injury, studies of long-term physical function in acute lung injury survivors have consistently reported poorer quality of life persisting years into recovery for reasons that are not completely understood. We sought to determine if pulmonary dysfunction is independently associated with functional impairment among acute lung injury survivors and to determine if high-resolution computed tomography could be used to predict its development. Design: Secondary analysis of data from a randomized controlled trial in acute lung injury. Setting: ICUs at three academic medical centers. Patients: Patients diagnosed with acute lung injury who had highresolution computed tomography scans performed at 14 and/or 180 days after diagnosis. Interventions: None. Measurements and Main Results: An objective radiologic scoring system was used to quantify patterns present on chest highresolution computed tomography obtained at 14 and 180 days in patients with acute lung injury. These scores were correlated in univariable and multivariable analyses with pulmonary function testing and quality of life survey data obtained at 180 days. Eighty-nine patients had evaluable data at day 14, and 47 at 180 days. At 180 days, increased radiologic scores for reticulation were associated with a decreased total lung capacity, forced vital capacity, and diffusing capacity for carbon monoxide (p values all < 0.002). Decrements in quality of life attributable to pulmonary dysfunction were most strongly associated with higher radiologic scores. Additionally, radiologic scores at 14 days independently predicted poorer quality of life at 180 days, accounting for age, severity of illness, pneumonia as the acute lung injury risk factor, and length of time on mechanical ventilation. Conclusions: Among survivors of acute lung injury, increasing chest high-resolution computed tomography involvement correlated with restrictive physiology and poorer health-related quality of life, implicating pulmonary dysfunction as a potential contributor to activity limitation in these patients. (Crit Care Med 2013; 41:445-456) 
D espite the lack of specific medical therapies to treat acute lung injury (ALI), mortality in this disorder has decreased to approximately 20%-30% in academic medical centers and remained relatively static during the past decade (1, 2) , resulting in an increasing number of ALI survivors. Given the bilateral, severe lung involvement that is the sine qua non of ALI, coupled with the ubiquitous use of mechanical ventilation in these patients, it seems plausible that pulmonary dysfunction could contribute to poorer healthrelated quality of life (HRQOL) among ALI survivors. Nevertheless, investigations have consistently attributed long-term functional impairment in survivors to neuromuscular weakness (3) (4) (5) , whereas the contribution of residual pulmonary dysfunction has received less attention (6, 7) .
Although prior investigations examining pulmonary function testing (PFT) in ALI survivors have reported normalization of median values for most parameters within months, approximately 25% of survivors exhibit a physiologic pattern consistent with restriction. This observation is exemplified in one well-characterized cohort of ALI survivors followed by Herridge et al (3) , where the percent-predicted forced vital capacity (FVC), total lung capacity (TLC), and diffusing lung capacity for carbon monoxide (DLCO) were all < 80% 1 yr after diagnosis, findings that persisted out to 5 yrs (4) . Recent investigations in ALI survivors cared for with a low tidal volume ventilation strategy have confirmed these observations at 6 to 12 months (5) (6) (7) . Published data suggest poorer quality of life in these ALI survivors (3, 5, 6) , with reported correlations between pulmonary physiology and quality of life (5, 6) . However, it is unclear whether PFT abnormalities observed in ALI survivors are primarily from pulmonary or neuromuscular pathology because neuromuscular weakness has the potential to present as restrictive abnormality on PFTs. Therefore, the contribution of persistent pulmonary pathology to quality of life in ALI survivors remains incompletely understood.
Establishing the relative contribution of pulmonary impairment vs. neuromuscular weakness to quality of life in ALI survivors has potentially important ramifications for therapy. To address these issues, we examined prospectively collected data from a cohort of ALI patients enrolled in a randomized controlled trial of granulocyte-macrophage colony stimulating factor. We hypothesized that among ALI survivors, 180 days (6 months) after diagnosis, the extent of chest high-resolution computed tomography (HRCT) reticulation would correlate with PFT abnormalities suggesting restrictive dysfunction, and with poorer quality of life measured using validated questionnaires. Additionally, we postulated that the extent of chest HRCT reticulation at 14 days after ALI diagnosis would be associated with the subsequent development of PFT abnormalities consistent with restriction, and impaired quality of life 180 days after diagnosis.
MATERIALS AND METHODS
Data were derived from an National Institutes of Health-sponsored Specialized Centers of Clinically Oriented Research proj-ect investigating the efficacy of granulocyte-macrophage colony stimulating factor in a double blind randomized controlled trial for ALI (8) .
Subjects Examined
Individuals meeting criteria for ALI or adult respiratory distress syndrome by the American-European Consensus Conference definition were considered for enrollment (9) . Patients with evidence of pre-existing chronic lung disease, including a history of Global Initiative for Obstructive Lung Disease stage III-IV chronic obstructive pulmonary disease or interstitial lung disease (from any cause), were excluded. Enrolled subjects received standardized ventilator management based upon Adult Respiratory Distress Syndrome Network protocols (10) . For our analysis, we evaluated patients with chest HRCTs performed at 14 and/or 180 days after ALI diagnosis and with PFTs available at 180 days after diagnosis. Reasons for excluded patients not having had these tests performed included death (either prior to 14 days or prior to 180 days), inability to safely tolerate HRCT per attending physician, lack of transportation to follow-up site, persistent hospitalization at scheduled time for follow-up, patient unwilling to proceed with study, investigator withdrawal of patient from the study, or study being halted by sponsor prior to completion of the 180-day follow-up. Clinical data collected in the parent trial were used in our analyses. Mean daily tidal volume, positive end-expiratory pressure, and plateau pressure exposures were calculated by summing all available daily values for these parameters collected while patients were on mechanical ventilation, and dividing by the total number of days on mechanical ventilation.
HRCT Scans
Chest HRCTs were performed at 14 ± 2 and/or 180 days post-ALI diagnosis. Mechanically ventilated patients were on ≥ 10 cm H 2 0 positive end-expiratory pressure during the HRCT (11) . All patients underwent imaging at end-inspiration. Sections were obtained with 1.25-mm collimation and were reconstructed by using a high-spatial-frequency algorithm. All images were viewed at window settings optimized for assessment of lung parenchyma (window width, 1300 HU; window level, −500 HU). Completed HRCTs were evaluated by two chest radiologists using established methods (12, 13) . Images at five levels were assessed: aortic arch, 1 cm above the dome of the right hemidiaphragm, and three additional levels equally spaced between these two levels. At each level, lungs were divided into anterior and posterior zones by drawing a horizontal line across the image, creating four quadrants for analysis per level. Specific radiologic patterns were quantified in each quadrant, including ground-glass opacification (GGO), intense parenchymal opacification (IPO), and reticulation. The extent of involvement for each pattern was assigned a numerical score, where 0 = no involvement; 1 = <5% involvement/minimal/not normal; 2 = 5%-25% involvement; 3 = 26%-49% involvement; 4 = 50%-75% involvement; and 5 = >75% involvement. For each radiologic pattern, the average score (range, 0-20) was calculated by summing all quadrant values for each of slice, adding these values together, and dividing by the number of slices with complete data. Missing data were scored as 0. Higher scores indicated more involvement by a given pattern.
Follow-Up of ALI Survivors
In addition to the 180-day chest HRCT scan, patients underwent additional testing at 180 days after diagnosis including measurement of medical research council (MRC) scores (14-16) and PFTs. Additionally, patients completed short form (SF)-36 questionnaires (3) (4) (5) (6) 17) and St George's respiratory questionnaires (SGRQ) (6, (18) (19) . A clinically meaningful change in one's SF-36 physical function score is 5 points (17), whereas a clinically meaningful change in the SGRQ is 4 points (18) .
Statistical Analyses
Analyses with continuous data were performed with Student's t test or Wilcoxon's rank sum test. Categorical data were analyzed using Fisher's exact test. Correlation coefficients between continuous data were calculated by Spearman's method. Linear regression was used to determine the association between HRCT scores (both from the 14-day and 180-day time points) and PFT parameters with 1) SF-36 scores or 2) SGRQ scores, adjusting for potential confounders in these models. Finally, for some analyses, patients were stratified as having restrictive impairment (FVC and residual volume [RV], both < 80% predicted) or not having restrictive impairment (FVC or RV ≥ 80% predicted) (20) (21) . Changes in HRCT scores over time in patients stratified using these criteria were evaluated using repeated measure analysis of variance. Two-sided p values of < 0.05 were deemed to be significant. JMP software (version 9; SAS Institute, Inc., Cary, NC) was used in analyses.
RESULTS

Description of Cohort
The overall cohort was comprised of 89 patients who had PFTs and/or HRCTs available for analysis ( Fig. 1) . Overall demographic data for the 14-and 180-day groups are presented in Table 1 . These 89 patients had Acute Physiology and Chronic Health Evaluation (APACHE) II scores of 18.1 ± 7.4. Clinical characteristics of the 47 included patients who returned for the 180-day follow-up were similar to the 42 included patients who did not return (p > 0.10 for all comparisons). Examination of data on the 67 patients enrolled in the parent trial, but not excluded in our final cohort of 89 patients, revealed a 43% 28-day mortality that would clearly limit follow-up, as well as higher severity of illness scores, and fewer ventilator-, intensive care unit-and hospital-free days, along with a higher average positive end-expiratory pressure and plateau pressure exposure. The percentage of patients among those excluded also contained a greater absolute percentage of African-Americans.
Key Features of HRCTs and 180-Day Data
HRCT average scores for reticulation, GGO, and IPO patterns were examined at each time point. For all three patterns, scores significantly decreased over time (p < 0.05 for all comparisons, Fig. 2 ). Unique HRCT scores and the overall HRCT score within patients who had two available scans (the first at day 14 and the second at day 180) were moderate-to-highly correlated (reticulation, r = 0.60; GGO, r = 0.54; IPO, r = 0.45; and overall, r = 0.68). Median values for the majority of PFT parameters examined at 180 days in the 47 patients were > 80% predicted ( Table 2) . However, as reported previously, approximately 25% of survivors had abnormal PFT values (defined as values < 80% predicted). Five of the 47 subjects (11%) had MRC total scores ≤ 48 at 180 days, consistent with neuromuscular weakness (15, 16) . Median role physical SF-36 scores were most abnormal in these ALI patients at 180 days; for the SGRQ domains, activity scores were most abnormal.
Among ALI Survivors, 180-Day Chest HRCT Scores Correlate With 180-Day PFT Parameters
To address our hypothesis that restrictive dysfunction specifically because of pulmonary disease is present among a subset of ALI survivors, the relationship between HRCT scores and PFT parameters were examined from patients who had Figure 1 . Derivation of study cohort from parent trial. *Six subjects had pulmonary function testing performed at 180 days, but did not undergo a highresolution computed tomography (HRCT) of the chest at 14 days while in-patients. Eighty patients in the included group were randomized to study drug (43 granulocyte-macrophage colony stimulating factor/37 placebo). ALI = acute lung injury; PFTs = pulmonary function testing; HRQOL = health-related quality of life. both tests performed at 180 days (top half of Table 3 ). Higher reticulation scores were strongly associated with a decreased FVC (r = −0.60, p = 0.0004), whereas higher GGO scores were strongly associated with a decreased TLC (r = −0.50, p = 0.001) and RV (r = −0.50, p = 0.007). The IPO score was inversely associated with the DLCO (r = −0.60, p = 0.0004). Overall HRCT scores were mostly strongly associated with a decreased TLC (r = −0.60, p = 0.003). Notably, not all patients with abnormally low PFT values had concurrently elevated HRCT scores at the 180-day time point (Supplemental Fig. 1 , http://links.lww.com/CCM/A535).
Among ALI Survivors, 180-Day HRCT Scores Correlate With 180-Day HRQOL
To determine if the degree of HRCT abnormalities in ALI survivors indicated pulmonary dysfunction that affects quality of life, HRCT scores were examined in association with SF-36 and SGRQ scores. In 37 patients who had undergone both HRCT Table 4 ). However, reticulation and overall HRCT scores at 180 days demonstrat-ed a moderate-to-strong correlation with poorer SGRQ impacts scores, activity scores, and total scores (r = 0.50 to 0.60, p < 0.003 for all comparisons; top of Table 5 ). Relationships between reticulation HRCT scores with quality of life indices were most pronounced, as illustrated in Figure 3 .
PFT Parameters at 180 Days Are Associated With Clinical Factors and HRQOL
Using these data, moderate-to-strong associations between the FVC, TLC, and DLCO (uncorrected) and SF-36 parameters (r = 0.50 to 0.60, Supplemental Digital Content 2, http://links.lww.com/CCM/A535) were observed, whereas somewhat weaker negative associations were observed between the 180-day SGRQ scores and the 180-day FVC and TLC (r = −0.40 to −0.50, Supplemental Digi- tal Content 2, http://links.lww.com/CCM/A535). We examined the relationship between PFTs and characteristics of critical illness, and determined that pulmonary-specific clinical patient factors were also associated with 180-day PFT variables, including the average plateau pressure exposure (vs. TLC, r = −0.55, p = 0.0001; vs. FVC, r = −0.34, p = 0.02) and the number of ventilator-free days (vs. DLCO, r = 0.41, p = 0.005). Similarly, pneumonia as a primary or secondary risk factor for ALI was associated with a lower RV (88% ± 21% vs. 112% ± 37%, p = 0.01), whereas a primary pulmonary cause for ALI (e.g., pneumonia or aspiration) was associated with a higher forced expiratory volume in first second/FVC ratio (83% ± 8% vs. 74% ± 7%, p = 0.0002); no relationship between the qualifying PaO 2 /FIO 2 and any PFT parameter was observed. Neither APACHE II scores nor week 1 Sequential Organ Failure Assessment scores correlated with any PFT variable at 180 days. However, at 180 days, the MRC score displayed a modest relationship with FVC (r = 0.41, p = 0.004) and DLCO (uncorrected; r = 0.42, p = 0.005). 
HRCT Scores at 180 Days Are Associated With Pulmonary-Specific Clinical Factors
As with 180-day PFTs, pulmonary-specific indices in ALI patients were also associated with 180-day chest HRCT scores, including average positive end-expiratory pressure exposure (r = 0.38, p = 0.02 vs. GGO; r = 0.33, p = 0.05 vs. HRCT total score) and average plateau pressure exposure (r = 0.37, p = 0.03 vs. reticulation; r = 0.54, p = 0.0007 vs. GGO; r = 0.48, p = 0.003 vs. HRCT total score). Furthermore, a diagnosis of pneumonia as either a primary or secondary risk factor for ALI was associated with significantly higher chest HRCT scores at 180 days (3.2 [intraquartile range 1.6-10.1] vs. 1.8 [intraquartile range 0-3.4], p = 0.03 for the difference in overall HRCT score between groups). There were no significant differences in HRCT scores between patients with primary pulmonary vs. those with nonpulmonary etiologies of ALI, and as was seen with PFT data, no significant relationships were observed between any HRCT score and APACHE II score, Sequential Organ Failure Assessment score, qualifying PaO 2 /FIO 2 ratio, or the number of days on the ventilator (p values, all >0.05).
In contrast to what was observed with PFTs, no significant associations between 180-day MRC scores and chest HRCT scores for reticulation (p = 0.33), GGO (p = 0.70), or IPO (p = 0.46) were observed.
Pulmonary Dysfunction Is Independently Associated With HRQOL in ALI
Multivariable analyses were performed to understand the influence of pulmonary dysfunction, neuromuscular weakness, and severity of illness on 180-day HRQOL. At 180 days, the FVC was the only variable independently associated with the SF-36 physical health subtotal score when 180-day overall HRCT score, the TLC value, MRC score, APACHE II score, age, number of days on the ventilator, average plateau pressure exposure, and pneumonia as ALI risk factor (yes/no) were included in the model (R 2 for model 0.34, β for FVC 0.75 ± 0.16, p < 0.0001). In contrast, the 180-day chest HRCT overall score (β = 0.99, p = 0.07) as well as FVC (β = −0.49, p = 0.03) were both associated with a poorer SGRQ total score at 180 days, accounting for these same potential confounders (R 2 for model 0.37).
Chest HRCT Scores at 14 Days Predict Restrictive PFT Abnormalities at 180 Days
To determine if radiologic patterns on chest HRCTs obtained at 14 days after ALI diagnosis would correlate with restrictive physiology at 180 days, data from 43 ALI patients who had had both studies performed were examined (bottom of Table 3 ). Reticulation scores at day 14 were associated with a lower 180-day TLC (r = −0.61, p < 0.0001) and DLCO (r = −0.50, p = 0.0005). The overall HRCT score was similarly associated with these two parameters, and with a decreased RV (r = −0.50, p = 0.003). GGO and IPO scores were also inversely associated with TLC. Figure 4 highlights the relationships between 14-day chest HRCT scores and percent-predicted TLC. When patients were stratified on the presence or absence of restrictive physiology at 180 days (using the criteria of FVC and RV < 80%, yes or no), reticulation, GGO, IPO, and overall HRCT scores all decreased significantly over time for each group of patients (p values < 0.03 within groups change over time). However, HRCT scores in the restricted group were significantly higher at both the 14-and 180-day time points for all pattern scores and the overall score (reticulation, p < 0.0001; GGO, p = 0.0001; IPO, p = 0.0007; overall, p < 0.0001 for comparisons between restricted and nonrestricted groups).
Chest HRCT Patterns at 14 Days Predict 180-day HRQOL
To determine if 14-day HRCT scores could be utilized in the prediction of 180-day HRQOL, correlations between these data were evaluated. As illustrated in the bottom of Table 4 , higher day 14 chest HRCT reticulation and overall scores demonstrated strong correlations with poorer SF-36 role physical (r = −0.50, p = 0.0003; r = −0.50, p = 0.001, respectively), and with the physical health subtotal (r = −0.50, p < 0.001; r = −0.50, p = 0.002, respectively) scores at 180 days. Similarly, when 14-day HRCT scores were compared with SGRQ scores from 180 days, moderate-to strong correlations (suggesting poorer quality of life) were noted for activity, impact, and total SGRQ scores in relationship to scores for reticulation, GGO, and the overall HRCT score (bottom of Table 5 ). Figure 5 illustrates some of the key relationships between reticulation HRCT scores with quality of life indices where regression coefficients demonstrated the most pronounced correlations.
HRCT Scores at 14 Days Are Associated With Pulmonary-Specific Clinical Factors
To examine potential clinical influences on the 14-day HRCT patterns, clinical variables were examined in the context of HRCTs. Higher overall HRCT scores were associated with fewer ventilatorfree (r = −0.34, p = 0.002), intensive care unit-free (r = −0.40, p = 0.0002), and hospital-free (r = −0.45, p < 0.0001) days; no relationships between this HRCT value and either age, qualifying PaO 2 /FIO 2 , APACHE II, or week 1 Sequential Organ Failure Assessment scores were evident. Overall HRCT scores did not differ based on pulmonary vs. nonpulmonary etiology of ALI; however, in patients who had pneumonia as either a primary or secondary ALI etiology, the median 14-day score was 15 (intraquartile range 9-25) vs. 12 (intraquartile range 4-17; p = 0.04). No differences in 14-day HRCT scores were observed that varied according to sex, randomization to active study, drug, race, or 28-day survival.
HRCT Scores at 14 Days Are Independently Associated With HRQOL in ALI Survivors at 180 Days
In multivariable analyses, day 14 chest HRCT reticulation scores were independently associated with SF-36 physical function (p = 0.04), role physical (p = 0.0004), and physical health subtotal (p = 0.005) scores at 180 days, accounting for the patient's age, the number of days on the ventilator, whether or not the patient had pneumonia as an ALI risk factor, and severity of illness (APACHE II scores). The GGO and overall HRCT scores were also independently related to these SF-36 domains, accounting for these covariates. The parameter estimates were the highest when 14-day HRCT reticulation scores were fit in these models (see Supplemental Digital Content 3, http://links.lww. com/CCM/A535).
Chest HRCT reticulation scores were also determined to be independently associated with SGRQ activity scores (p = 0.0002), impact scores (p = 0.008), and the total score (p = 0.002) in a multivariable model, again accounting for patient age, number of ventilated days, whether or not the patient had pneumonia as an ALI risk factor, and severity of illness. Similarly, GGO and overall scores were independently correlated with SGRQ activity, impact, and total scores accounting for these same four covariates. Once again, the parameter estimates were highest when 14-day HRCT reticulation scores were included in these models (Supplemental Digital Content 3, http://links.lww. com/CCM/A535).
DISCUSSION
In these investigations, using prospectively collected data from ALI patients, we observed that a subset of patients has both PFT and HRCT abnormalities 180 days after diagnosis. Furthermore, at this time point, the degree of chest HRCT reticulation, GGO, and IPO (and their combination) correlated with a lower FVC, TLC, RV, and DLCO, consistent with restrictive pulmonary dysfunction. Additionally, as 180day reticulation HRCT scores increased, a clinically relevant decrease in HRQOL was evident. In multivariable analyses, the quantity of HRCT involvement and the FVC at 180 days were independently associated with impaired HRQOL on validated surveys, independent of neuromuscular weakness, age, and severity of illness. The association between 180-day HRCT abnormalities, restrictive pulmonary physiology, and quality of life suggests that persistent respiratory dysfunction has a measureable impact on the physical capabilities of ALI survivors. Separate analyses using data from HRCTs obtained at day 14 after ALI diagnosis revealed a negative association between reticulation and overall HRCT scores with 180day TLC, RV, and DLCO. These 14-day HRCT scores also predicted poorer HRQOL, independent of age, severity of illness, pneumonia as the etiology of ALI, and length of time on the ventilator. These latter data suggest that HRCTs obtained during hospitalization could aid in prognostication of long-term outcomes for ALI survivors.
Numerous investigations involving ALI survivors have reported poorer quality of life persisting months to years after the acute phase of illness (3) (4) (5) (6) (7) . PFTs performed in these patients have revealed physiologic abnormalities similar to our observations. Both Heyland et al (6) and Orme et al (5) linked specific PFT abnormalities found in ALI survivors to long-term functional outcomes, observing that SF-36 and SGRQ values correlated significantly with PFT results among ALI survivors at 6 and 12 months. Our data support these earlier observations, and the magnitude of the correlations we observed in univariate analyses between the FVC, TLC, and DLCO with SF-36/SGRQ parameters was comparable to their reports.
Our data demonstrated that certain pulmonary-specific clinical factors (e.g., a diagnosis of pneumonia) were associated with both HRCT scores and PFT parameters; in contrast, the MRC score, indicating neuromuscular strength, only correlated with PFTs at 180 days. Also, at 180-day follow-up, we determined that individual PFT parameters were more strongly associated with the SF-36, whereas HRCT scores were more strongly associated with the SGRQ. Notably, the SGRQ focuses on quantifying respiratory symptoms (e.g., cough or wheezing), the effect of respiratory problems on the ability to work or perform activities of daily living, and the impact of respiratory problems on daily life. The pulmonary-specific nature of these questions contrasts with SF-36 question content that does quantitate physical capabilities, but does not explicitly query lung symptomatology. Along these same lines, lung appearance on HRCT of the chest would be expected to reflect pulmonary-specific pathology. Therefore, the stronger associations between SGRQ and chest HRCT (in comparison to SF-36 and chest HRCT) as we observed provide additional support for HRQOL dysfunction among ALI survivors specifically referable to residual pulmonary impairment.
As lung biopsies are usually not performed in patients with ALI, patterns observed in chest computed tomography im-aging have indirectly provided insight to the natural history of ALI, and have an acceptable risk in these patients. HRCT scanning of the chest days after ALI diagnosis typically displays radiographic ground glass and intense parenchymal opacification patterns (12) , consistent with inflammation and airspace disease, whereas a predominantly reticular pattern is observed months later (12, 22) , despite the use of low tidal volume ventilator strategies (7) . These dynamic HRCT changes in ALI prompted the development of a scoring system to define the correlation between radiologic patterns and clinical outcomes. Investigators reported that a higher overall composite score correlated with poorer short-term outcomes in ALI, including mortality (13) . Our work provides evidence that HRCT radiologic scoring, particularly for reticulation, could provide useful information regarding respiratory dysfunction among ALI survivors.
An abnormal fibroproliferative response to ALI represents one possible explanation for the physiologic and radiologic abnormalities we observed. Translational ALI investigations suggest that pulmonary fibroproliferation begins within 72 hrs of ALI diagnosis (23) (24) (25) (26) , and that profibrotic activity is associated with important clinical outcomes, including mortality (23) (24) (25) . Histologically, moderate to severe fibrosis has been demonstrated in 20% of ALI patients within 10 days of diagnosis, and has been associated with increased mortality (57%) (27) . Nevertheless, more recent investigations have called the relevance of fibroproliferation to long-term ALI outcomes into question. Some investigations support that profibrotic mechanisms are harmful (28-29), but others have reported a relationship between profibrotic mechanisms and survival (30), as well as less time on mechanical ventilation (31) . At the current time, the exact relationship of mediators and cells involved in long-term functional outcomes, including restrictive pathophysiology, is not well-established.
Although our findings with this cohort of ALI patients are intriguing, they are not without limitations. First, the number of patients with data available at both 14 and 180 days was modest, and patients were racially homogeneous. The functional (and vital) status of some enrolled patients who did not follow-up is unknown. However, given that the data were derived from a multicenter clinical trial where numerous possible confounders were controlled, we think that our observations provide novel insight to the potential utility of HRCT in understanding ALI pathogenesis. Second, radiographic HRCT patterns were scored by two chest radiologists with HRCT interpretation experience. Whether radiologists without such HRCT interpretation experience would provide similar interpretations of these patterns is unknown. Additionally, MRC scores could have varied from observer to observer across sites affecting the validity of this outcome variable. However, clinicians performing these examinations did not have access to other long-term outcome variables, thus diminishing the potential for bias. Recently published investigations examining the reproducibility of MRC scores in patients, including critical illness survivors, suggest that inter-rater reliability is in fact quite good in this population (32, 33) . Nevertheless, formal nerve conduction studies/electromyographic testing in weak patients (with abnormal MRC scores) would have been helpful in confirming true neuromuscular dysfunction in this population (34) . Finally, because enrolled patients were not screened with PFTs nor HRCT prior to enrollment, it is possible that some had preexisting lung disease that confounded our results. However, a history of preexisting lung disease was a specific exclusion criterion for this study. Furthermore, it seems equally possible that ALI contributed to persistently higher HRCT scores at 180 days in a subset of survivors, particularly given the relatively young age of the cohort (making diseases such as idiopathic pulmonary fibrosis less likely), and the severity of the patients' illness. Overall, the strength of these investigations lies in the prospective data collection (including physiologic and radiologic data) in a sizable number of ALI patients from multiple sites who were also receiving standardized ICU care, including a low tidal volume ventilator strategy.
CONCLUSIONS
Based on physiologic and radiologic data, and their correlation with quality of life measures, symptomatic pulmonary dysfunction is present in a substantial number of ALI survivors 180 days after the diagnosis of illness, independent of neuromuscular weakness. Furthermore, quantifying the extent of chest HRCT involvement 14 days after ALI diagnosis may represent a useful, noninvasive strategy to predict symptomatic pulmonary dysfunction in survivors. Our observations pave the way to establish the prevalence of pulmonary dysfunction among ALI survivors more accurately, and to promote its earlier identification. Developing these concepts will enable the development of therapies to promote survival and enhance quality of life in ALI patients at risk for pulmonary dysfunction.
